51
|
Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Watanabe T, Hayashi M, Kanayama Y, Funahashi K, Asai S, Yoshioka Y, Takemoto T, Terabe K, Asai N, Ishiguro N. Longterm Efficacy and Safety of Abatacept in Patients with Rheumatoid Arthritis Treated in Routine Clinical Practice: Effect of Concomitant Methotrexate after 24 Weeks. J Rheumatol 2015; 42:786-93. [DOI: 10.3899/jrheum.141288] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/23/2015] [Indexed: 11/22/2022]
Abstract
Objective.Our study aimed to evaluate the longterm efficacy and safety of abatacept (ABA), and to explore factors that increase its longterm efficacy in patients with rheumatoid arthritis (RA) treated in routine clinical practice.Methods.There were 231 participants with RA treated with ABA who were prospectively registered in a Japanese multicenter registry. They were followed up for at least 52 weeks.Results.Mean age of the patients was 64.3 years, mean disease duration was 12.1 years, mean 28-joint Disease Activity Score (DAS28)-C-reactive protein was 4.49, and 48.5% of patients were concomitantly treated with methotrexate (MTX). Overall retention rate of ABA was 77.1% at 52 weeks; 14.8% of patients discontinued because of inadequate response and 3.5% because of adverse events. The proportion of patients achieving DAS28-defined low disease activity (LDA) significantly increased from baseline to 52 weeks (7.3% to 43.8%, p < 0.01); 40.9% of patients who did not achieve LDA at 24 weeks had more than 1 categorical improvement in DAS28-defined disease activity at 52 weeks. Multivariate logistic regression revealed concomitant MTX use to be an independent predictor of the categorical improvement in DAS28-defined disease activity from 24 to 52 weeks (adjusted OR 3.124, p = 0.010).Conclusion.In routine clinical practice, ABA demonstrated satisfactory clinical efficacy and safety in patients with established RA for 52 weeks. The clinical efficacy of ABA increased with time even after 24 weeks, and this was strongly influenced by concomitant MTX use. Our study provides valuable real-world findings on the longterm management of RA with ABA.
Collapse
|
52
|
Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer 2015; 112:1501-9. [PMID: 25867264 PMCID: PMC4453666 DOI: 10.1038/bjc.2015.101] [Citation(s) in RCA: 500] [Impact Index Per Article: 55.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2014] [Revised: 02/19/2015] [Accepted: 02/19/2015] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND PD-L1 (programmed cell death 1 ligand 1) on tumour cells suppresses host immunity through binding to its receptor PD-1 on lymphocytes, and promotes peritoneal dissemination in mouse models of ovarian cancer. However, how PD-L1 expression is regulated in ovarian cancer microenvironment remains unclear. METHODS The number of CD8-positive lymphocytes and PD-L1 expression in tumour cells was assessed in ovarian cancer clinical samples. PD-L1 expression and tumour progression in mouse models under conditions of altering IFN-γ signals was assessed. RESULTS The number of CD8-positive cells in cancer stroma was very high in peritoneally disseminated tumours, and was strongly correlated to PD-L1 expression on the tumour cells (P<0.001). In mouse models, depleting IFNGR1 (interferon-γ receptor 1) resulted in lower level of PD-L1 expression in tumour cells, increased the number of tumour-infiltrating CD8-positive lymphocytes, inhibition of peritoneal disseminated tumour growth and longer survival (P=0.02). The injection of IFN-γ into subcutaneous tumours induced PD-L1 expression and promoted tumour growth, and PD-L1 depletion completely abrogated tumour growth caused by IFN-γ injection (P=0.01). CONCLUSIONS Interferon-γ secreted by CD8-positive lymphocytes upregulates PD-L1 on ovarian cancer cells and promotes tumour growth. The lymphocyte infiltration and the IFN-γ status may be the key to effective anti-PD-1 or anti-PD-L1 therapy in ovarian cancer.
Collapse
|
53
|
Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Fukaya N, Hayashi M, Tsuboi S, Kanayama Y, Funahashi K, Hanabayashi M, Hirabara S, Asai S, Yoshioka Y, Ishiguro N. Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study. Rheumatology (Oxford) 2014; 54:854-9. [DOI: 10.1093/rheumatology/keu418] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2014] [Indexed: 11/13/2022] Open
|
54
|
Seo Y, Yoshizaki K, Hayashi K, Tamari K, Isohashi F, Suzuki O, Yoshioka Y, Ogawa K. Systematic Linear-Quadratic Analysis for Radiosensitization In Vitro: Implications for Hypofractionated Radiation Therapy in the Combined Modality Approaches. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.2312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
55
|
Isohashi F, Yoshioka Y, Mabuchi S, Seo Y, Suzuki O, Sumida I, Otani Y, Kimura T, Ogawa K. Dose-Volume Analysis of Predictors for Acute Hematologic Toxicity in Patients With Cervical Cancer Treated With Postoperative Pelvic Radiation Therapy and Concurrent Nedaplatin-Based Chemotherapy. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
56
|
Ota S, Sumida I, Yoshioka Y, Inoue S, Ogawa K. Feasible Strategy for Reduction of Individual Human Failures in External Radiation Therapy Workflow. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.2165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
57
|
Nishio S, Mikami Y, Otsuki T, Yaegashi N, Satoh T, Yoshikawa H, Saitoh M, Okamoto A, Kasamatsu T, Miyamoto T, Shiozawa T, Yoshioka Y, Konishi I, Kojima A, Takehara K, Kaneki E, Kobayashi H, Ushijima K, Kamura T. Recurrence Patterns of Gastric-Type Adenocarcinoma (Gas) of the Uterine Cervix: a Subset Analysis of the Gynecologic Cancer Study Group of the Japan Clinical Oncology Group (Jcog) Gas Multicenter Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu338.48] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
58
|
Kojima T, Takahashi N, Funahashi K, Asai S, Hirabara S, Hanabayashi M, Yoshioka Y, Yabe Y, Ishiguro N. SAT0063 Importance of Concomitant Methotrexate with TOCILIZUMAB and Assessment of Structual Damage for Achieving Better Clinical Outcomes for Rheumatoid Arthritis Patients with High Disease Activity: an Observational Cohort Study. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
59
|
Hirabara S, Kojima T, Takahashi N, Hirano Y, Yabe Y, Kaneko A, Funahashi K, Hanabayashi M, Asai S, Yoshioka Y, Ishiguro N. SAT0251 Three Biological DMARDS of Different Classes Exhibit Equivalent Efficacy in Rheumatoid Arthritis Patients with Inadequate Response to Anti-TNF Monoclonal Antibodies. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
60
|
Hanabayashi M, Kojima T, Takahashi N, Kida D, Funahashi K, Hirabara S, Asai S, Yoshioka Y, Ishiguro N. SAT0237 The Clinical Efficacy and Safety of Abatacept for Rheumatoid Arthritis from Japanese Multi-Center Registry: 2-Year Outcomes. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
61
|
Funahashi K, Kojima T, Takahashi N, Hanabayashi M, Hirabara S, Asai S, Yoshioka Y, Yabe Y, Ishiguro N. FRI0332 Considering the Maintenance Treatment with TOCILIZUMAB for Rheumatoid Arthritis, We HAD Better Treat in Combination with Mtx. the Report of 2Years Multi-Center Clinical Practice. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
62
|
Yamaguchi K, Amano Y, Matsumura N, Mandai M, Abiko K, Hamanishi J, Yoshioka Y, Baba T, Konishi I. HNF1B contributes to resistance to oxidative stress through modification of metabolism in ovarian clear cell carcinoma. Gynecol Oncol 2014. [DOI: 10.1016/j.ygyno.2014.03.232] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
63
|
Asai S, Kojima T, Oguchi T, Takahashi N, Funahashi K, Hanabayashi M, Hirabara S, Yoshioka Y, Ishiguro N. OP0069 Concomitant Methotrexate Affect the Incidence of Large Joint Replacement Surgery in the Rheumatoid Arthritis Patients Treated with Etanercept. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
64
|
Hirano Y, Kanayama Y, Yoshioka Y, Kanda H, Kaneko A, Kojima T, Ishiguro N. AB0478 Influences of Disease Activity at Initiation of Iguratimod, A Small-Molecule Antirheumatic Drug, on Efficacy of Iguratimod in Patients with Rheumatoid Arthritis: A Multicenter Study. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
65
|
Yanai H, Yoshioka Y, Yoshida H, Nakao Y, Plessis A, Yamaguchi M. Drosophila myeloid leukemia factor acts with DREF to activate the JNK signaling pathway. Oncogenesis 2014; 3:e98. [PMID: 24752236 PMCID: PMC4007195 DOI: 10.1038/oncsis.2014.13] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2013] [Revised: 02/27/2014] [Accepted: 03/03/2014] [Indexed: 12/29/2022] Open
Abstract
Drosophila myelodysplasia/myeloid leukemia factor (dMLF), a homolog of human MLF1, oncogene was first identified by yeast two-hybrid screen using the DNA replication-related element-binding factor (DREF) as bait. DREF is a transcription factor that regulates proliferation-related genes in Drosophila. It is known that overexpression of dMLF in the wing imaginal discs through the engrailed-GAL4 driver causes an atrophied wing phenotype associated with the induction of apoptosis. However, the precise mechanisms involved have yet to be clarified. Here, we found the atrophied phenotype to be suppressed by loss-of-function mutation of Drosophila Jun N-terminal kinase (JNK), basket (bsk). Overexpression of dMLF induced ectopic JNK activation in the wing disc monitored with the puckered-lacZ reporter line, resulting in induction of apoptosis. The DREF-binding consensus DRE sequence could be shown to exist in the bsk promoter. Chromatin immunoprecipitation assays in S2 cells with anti-dMLF IgG and quantitative real-time PCR revealed that dMLF binds specifically to the bsk promoter region containing the DRE sequence. Furthermore, using a transient luciferase expression assay, we provide evidence that knockdown of dMLF reduced bsk gene promoter activity in S2 cells. Finally, we show that dMLF interacts with DREF in vivo. Altogether, these data indicate that dMLF acts with DREF to stimulate the bsk promoter and consequently activates the JNK pathway to promote apoptosis.
Collapse
|
66
|
Takahashi N, Kojima T, Terabe K, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Fukaya N, Ishikawa H, Hayashi M, Tsuboi S, Kato D, Funahashi K, Matsubara H, Hattori Y, Hanabayashi M, Hirabara S, Yoshioka Y, Ishiguro N. Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients. Mod Rheumatol 2014. [DOI: 10.3109/s10165-012-0760-4] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
67
|
Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Fukaya N, Ishikawa H, Hayashi M, Tsuboi S, Kanayama Y, Kato D, Funahashi K, Matsubara H, Hattori Y, Hanabayashi M, Hirabara S, Terabe K, Yoshioka Y, Ishiguro N. Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity. Clin Rheumatol 2014; 33:39-47. [PMID: 24057092 PMCID: PMC3890049 DOI: 10.1007/s10067-013-2392-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2013] [Accepted: 09/08/2013] [Indexed: 11/06/2022]
Abstract
Favourable clinical results in rheumatoid arthritis (RA) patients with high disease activity (HDA) are difficult to achieve. This study evaluated the clinical efficacy of abatacept according to baseline disease activity compared to adalimumab and tocilizumab. This study included all patients registered in a Japanese multicenter registry treated with abatacept (n = 214), adalimumab (n = 175), or tocilizumab (n = 143) for 24 weeks. Clinical efficacy of abatacept in patients with HDA (DAS28-CRP > 4.1) and low and moderate disease activity was compared. Clinical efficacy of abatacept, adalimumab, and tocilizumab was compared in patients with HDA at baseline. In patients treated with abatacept, multivariate logistic regression identified HDA at baseline as an independent predictor for achieving low disease activity (LDA; DAS28-CRP < 2.7) [OR 0.26, 95 % CI 0.14-0.50] or remission (DAS28-CRP < 2.3) [OR 0.26, 95 % CI 0.12-0.56] at 24 weeks. In patients with HDA at baseline, logistic regression did not identify treatment with adalimumab or tocilizumab as independent predictors of LDA or remission compared to abatacept. Retention rates based on insufficient efficacy were significantly higher in patients treated with abatacept compared to adalimumab and lower than tocilizumab. Retention rates based on adverse events in patients treated with abatacept were significantly lower compared to tocilizumab. Clinical efficacy of abatacept was affected by baseline disease activity. There were no significant differences between the three different classes of biologics regarding clinical efficacy for treating RA patients with HDA, although definitive conclusions regarding long-term efficacy will require further research.
Collapse
|
68
|
Yoshioka Y, Suzuki O, Nakai Y, Uemura M, Nonomura N, Ogawa K. OC-0318: High-dose-rate brachytherapy as monotherapy for intermediate- and high-risk prostate cancer: Seven-year results. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)30423-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
69
|
Yamashita T, Kamada H, Kanasaki S, Maeda Y, Nagano K, Abe Y, Inoue M, Yoshioka Y, Tsutsumi Y, Katayama S, Inoue M, Tsunoda S. Epidermal growth factor receptor localized to exosome membranes as a possible biomarker for lung cancer diagnosis. DIE PHARMAZIE 2013; 68:969-973. [PMID: 24400444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Detection of drug-target proteins and biomarkers that are expressed in cancer tissue has significant potential for both diagnosis and treatment of cancer. However, current immuno-histochemical and cytogenetic analyses of biopsy specimens for pre-operational diagnosis are highly invasive and often difficult to apply to lung cancer patients. The purpose of this study was to evaluate the possible utility of determining epidermal growth factor receptor (EGFR) expression on exosomal membranes using a targeted ELISA with an anti-CD81 antibody as a capture antibody for lung cancer diagnosis. While soluble EGFR (sEGFR) levels in plasma were not remarkably different between lung cancer patients and normal controls, significantly higher exosomal EGFR expression levels were observed in 5/9 cancer cases compared to normal controls. These results suggest that measurement of exosomal protein levels could be useful for in vitro diagnosis, and that exosomal EGFR is a possible biomarker for characterization of lung cancer.
Collapse
|
70
|
Yoshikawa N, Shimbo T, Yoshioka Y, Yoshida K, Uesugi Y, Narumi Y. Sivelestat Sodium Hydrate Reduces Radiation-Induced Lung Injury in Mice by Inhibiting Neutrophil Elastase. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
71
|
Isohashi F, Akino Y, Otani Y, Suzuki O, Seo Y, Yoshioka Y, Ogawa K. Dose–Volume Analysis of Predictors for Gastrointestinal Complications in Patients With Cervical Cancer Treated With Postoperative Pelvic Radiation Therapy and Concurrent Nedaplatin-Based Chemotherapy. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
72
|
Abou-Taleb H, Yamaguchi K, Mandai M, Yamanoi K, Amano Y, Matsumura N, Baba T, Yoshioka Y, Hamanishi J, Konishi I. Role of ARID1A for the clinicopathologic characteristics of clear cell carcinoma (CCC) of the ovary. Gynecol Oncol 2013. [DOI: 10.1016/j.ygyno.2013.04.361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
73
|
Kato D, Kojima T, Funahashi K, Takemoto T, Yoshioka Y, Watanabe T, Takahashi N, Hattori Y, Hanabayashi M, Ishiguro N. THU0233 To Achieve the Boolean/Sdai Remission, the Intra-Articular Steroid Injection is the Useful Application for Rheumatoid Arthritis Patients Close to Remission. –Clinical and Ultrasonographic Evaluation. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
74
|
Hirabara S, Kojima T, Takahashi N, Hanabayashi M, Terabe K, Yoshioka Y, Ishiguro N. SAT0134 Clinical Efficacy of Abatacept in Rheumatoid Arthritis Patients with Prior Use of Tocilizumab; Results from Japanese Multicenter Registry System TBCR. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
75
|
Watanabe T, Kojima T, Takahashi N, Funahashi K, Kato D, Hattori Y, Hanabayashi M, Terabe K, Yoshioka Y, Ishiguro N. AB0793 Discordance between patients and physicians in their assessment of rheumatoid arthritis disease activity. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.3115] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|